{"entity":{"id":"expression-therapeutics","kind":"company","name":"Expression Therapeutics","aka":["Expression Therapeutics, Inc."],"tldr":"Expression Therapeutics, near Atlanta, makes cell and gene therapies. In cancer it programmes a patient's gamma-delta T cells to release a protein that pulls other immune cells onto the tumour, starting with neuroendocrine tumours.","summary":"Expression Therapeutics, Inc., headquartered in Tucker, Georgia, with manufacturing in West Chester Township, Ohio, develops gene therapies for haemophilia A and cell therapies for cancer. Its ADEPT-STAR approach expands a patient's own gamma-delta T cells and programmes them with its LENTeT gene transfer system to secrete a T-cell engager. The lead, ADEPT-STAR-NET-1, secretes a CD3 by SSTR2 bispecific engager for gastroenteropancreatic neuroendocrine tumours and is preclinical. A 2026 National Cancer Institute SBIR award funds ADEPT-STAR therapy for high-risk neuroblastoma.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://www.expressiontherapeutics.com/"},{"label":"Neuroendocrine tumour programme","url":"https://www.expressiontherapeutics.com/therapeutics-nets"},{"label":"NIH RePORTER: award 2R44CA281633-02A1","url":"https://reporter.nih.gov/project-details/11407954"}],"tags":[],"related":[],"cancers":["neuroendocrine","neuroblastoma"],"sections":["cell-therapy","immunotherapy"],"technologies":["gamma-delta-t-cell-therapy","t-cell-engager"],"targets":["sstr2"],"drugs":["adept-star-net-1"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website (home and neuroendocrine tumour pages) and the NIH RePORTER record read on 4 November 2026. The target used for neuroblastoma is not stated in the parts of the award read."],"hq":"Tucker, GA","country":"US","companyType":"cell-therapy","website":"https://www.expressiontherapeutics.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":1131730,"source":"https://reporter.nih.gov/project-details/11407954","note":"NCI SBIR (R44) award 2R44CA281633-02A1: ADEPT-STAR therapy for high risk neuroblastoma"}]},"route":"/companies/expression-therapeutics/","neighbours":{"cancer":[{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"gamma-delta-t-cell-therapy","kind":"technology","name":"Gamma-delta T cell therapy","route":"/technologies/gamma-delta-t-cell-therapy/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"}],"drug":[{"id":"adept-star-net-1","kind":"drug","name":"ADEPT-STAR-NET-1","route":"/drugs/adept-star-net-1/"}]}}